The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology (Inst)
Research Funding - Astellas Pharma (Inst); AstraZeneca/Merck (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Roche
 
Emmanuel S. Antonarakis
Honoraria - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Consulting or Advisory Role - AIkido Pharma; Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Orion; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Se Hoon Park
Honoraria - Merck; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Ono Pharmaceutical; Sanofi
 
Jeffrey C. Goh
Stock and Other Ownership Interests - ICON Cancer Care; Immutep
Honoraria - Ipsen; MSD Oncology
Consulting or Advisory Role - BMS; GlaxoSmithKline; Janssen Oncology; MSD
Speakers' Bureau - AstraZeneca/MedImmune; BMS; Ipsen; Janssen; MSD Oncology
Research Funding - BeiGene (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Raymond S. McDermott
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi
Speakers' Bureau - MSD Oncology
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Janssen-Cilag; Pfizer; Roche
 
Nuria Sala González
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Peter C.C. Fong
Consulting or Advisory Role - MSD
Travel, Accommodations, Expenses - Pfizer
 
Richard Greil
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Takeda
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; MSD; Novartis; Roche
 
Maria De Santis
Honoraria - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Basilea; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; Exelixis/Ipsen; Ferring; Gilead Sciences; Immunomedics; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; MSD Oncology; Novartis; Orion; Pfizer; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen
Consulting or Advisory Role - AAA HealthCare; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Basilea; Bayer; BioClin Therapeutics; BioSyn Healthy Pharma; Bristol-Myers Squibb; Ferring; Gilead Sciences; GlaxoSmithKline; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sandoz-Novartis; Sanofi; Seagen; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Roche; Roche/Genentech; Sanofi
 
Patricio Eduardo Yanez
Honoraria - AstraZeneca (Inst); BMS CHILE (Inst); MSD (Inst); Sanofi/Regeneron (Inst)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; MSD Oncology
Speakers' Bureau - AstraZeneca; BMS CHILE
 
Yi-Hsiu Huang
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Janssen; Pfizer
 
Stephen Begbie
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; Merck Serono; MSD Oncology; Pfizer
Research Funding - Astellas Medivation (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Pfizer/EMD Serono (Inst); Roche (Inst)
 
Felipe Rey
Honoraria - AstraZeneca; MSD
 
Gero Kramer
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Genzyme; Ipsen; Janssen; MSD; Novartis; Takeda
Research Funding - Bayer
 
Hiroyoshi Suzuki
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Health; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Janssen Oncology; Janssen Research & Development; Lilly; Lilly; MSD K.K; Nihon Medi-Physics; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Daiichi-Sankyo; Janssen; Nippon Shinyaku; Sanofi; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Ono Yakuhin (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Todd L. Saretsky
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Sameer R. Ghate
Employment - Merck Sharp & Dohme; Novartis
Stock and Other Ownership Interests - Advaxis (I); Agenus (I); AVEO (I); Bellicum Pharmaceuticals (I); Bellicum Pharmaceuticals (I); Calithera Biosciences (I); Idera (I); Mannkind; Provectus
 
Yi Cui
Employment - Merck
 
Jeri Kim
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Evan Y. Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Exelixis; Janssen; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Daiichi Sankyo (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)